Intermediate biomarkers of colon cancer: modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis.
In our attempts to evaluate the influence of chemopreventive agents on intermediate biomarkers of colon cancer, we have investigated the effect of D,L-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase and piroxicam, a non-steroidal anti-inflammatory drug (NSAID) on the expression levels of biochemically active p21ras, the protein product of cellular ras protooncogenes during the development of azoxymethane (AOM) induced colon carcinogenesis in male F344 rats in order to explore the plausibility of using p21ras as an intermediate biochemical marker of colon cancer. Groups of male F344 rats were fed the modified AIN-76A diets containing 0 or 150 p.p.m. piroxicam or 4000 p.p.m. DFMO and administered s.c. AOM dissolved in normal saline at a dose of 15 mg/kg body wt/week, once weekly, for 4 weeks. Vehicle control groups received s.c. equal vol of normal saline. Groups of animals were then killed at 0, 4, 16, 24 and 32 weeks after the last injection of AOM or saline and their colonic mucosa and tumors analyzed for biochemically active p21ras levels. AOM treatment significantly increased the expression of biochemically active p21ras. The AOM-induced expression of biochemically active p21ras was significantly suppressed by dietary DFMO and piroxicam. DFMO exerted a more pronounced inhibitory effect on AOM-induced colon tumor development as well as the expression of biochemically active p21ras. These results indicate that the determination of biochemically active p21ras may be effectively used in clinical chemoprevention trials as an intermediate end-point to monitor the colon carcinogenesis.
Singh
J
J
American Health Foundation, Division of Nutritional Carcinogenesis, Valhalla, NY 10595.
Kelloff
G
G
Reddy
B S
BS
D000345:Affinity Labels; D000818:Animals; D001397:Azoxymethane; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000378:metabolism*; D000518:Eflornithine / Q000494:pharmacology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006160:Guanosine Triphosphate / Q000378:metabolism; D008297:Male; D010894:Piroxicam / Q000494:pharmacology*; D016283:Proto-Oncogene Proteins p21(ras) / Q000187:drug effects / Q000378:metabolism*; D051381:Rats
D000345:Affinity Labels; D014408:Biomarkers, Tumor; D010894:Piroxicam; D006160:Guanosine Triphosphate; D016283:Proto-Oncogene Proteins p21(ras); D001397:Azoxymethane; D000518:Eflornithine